Finally, POST3 PDCs exhibited activated TGF-β signaling regulated by PDK1, SMAD2, TGFBR3, and ZEB1. The over-expression of TGF-β signaling and ZEB1 demonstrated that osimertinib-resistant cancer exhibited EMT pathway activation (Fig. 5C). This evidence concerns the gene SMAD2 and cancer.